Hi. Can you hear me? Yes, I can hear you. Okay. Yes, perfect.
Yes. So a couple of questions on Lacanbi. Congrats, very strong results. On slide number 16, you guys showed real world data where the incidence of ARIA is roughly thirteen percent. Right?
Compared to the Clarity AD trial, there you have twenty one point three percent ARIA incidents. So this is much, much lower. So any any reason why is this so much lower in the real world setting? Is it just because of it's a very small number of one hundred seventy eight patients? Yeah.
Thank you. Perhaps just a quick follow-up on your advantage on slide 18. Your advantage against Eli Lilly's Kisinla when it comes to ARIA. The data, the advantage is assuming Kisinla dosed using the original schedule. You know that Kisinla is now being dosed at a more gradual titration schedule.
Do you think you can maintain your ARIA advantage over Kisimla with their new slower dosing schedule? That's certainly very reassuring. If I could just add a quick question on slide number 28 for your China, like, can be sales. Right? Because of your your inventory building there.
So it looks like you are only looking to sell another 1,800,000,000.0 worth of Vallocambi in China. I just wanna confirm my understanding is correct. This looks fairly fairly low number for the rest of for the rest of the year, three quarters. Okay. Very good. Yeah. Thank you very much. Appreciate it.
Yes. Thank you for the question. I'm the chief clinical officer. Of course, your question, is focused on the preclinical AD indication. We have our AHEAD three four five study, and that is a protocol that has been agreed with the FDA and can truly evaluate preclinical AD.
And we're confident that by removing both protofibrils and plaque when present, we will have a positive result. However, there are differences in the trials from danatumab in which one third of the patients have global CDRs of point five, which is MCI, while in our head three, four, five trial, there are no patients with CDR some of global CDR higher than zero. So all patients in the trial are actually preclinical AD. And we believe that that will be a critical impact in the results of the trial. We have somewhat different endpoints.
Their endpoints are looking at the conversion to the next stage. We have a primary endpoint of PAC-five, which we believe is a more sensitive endpoint, and also secondary endpoints that are focused on change to the next stage of disease. So we believe that our study, more accurately represents the preclinical population, and our results, we expect to be robust. Thank you.
Just just just follow-up. You said preclinical. The really talking about presymptomatic. Are there any big difference between two definitions?
No. That's the same. So the well, obviously, if you have a CDR global of point five, you are not presymptomatic. You are symptomatic, and that's the definition of MCI. The preclinical means that the patient has no cognitive impairment and has either intermediate amyloid, which means it's building up, or elevated just as in the CLARITY AB trial but no symptoms.
So there's a difference in the two studies in what is being evaluated. People with symptoms already are covered by the existing label for both drugs. So their study is somewhat different than ours in the population they're studying. Is that clear?
Yes. Just one more. The biomarker. You're setting up any biomarker, pre symptomatic or preclinical patient? Yes.
Many, many biomarkers are being evaluated just as they were in Clarity AD, and that are many of the standard biomarkers such as p tau two seventeen, the a beta 42 to 40 ratio. We'll also be looking at our biomarker m t MTBR tau two four three, neurogranin, many, many.
Okay. So you have unde identified biomarkers already?
Yes. Many. And and in the protocol.
Okay. Alright. Thanks.